News
News Center
The 2020 Top 100 Chinese Pharmaceutical Industry List was released, and Jiuzhitang proudly made the cut!
来源：Jiuzhitang Group Official WeChat Account
2021-07-23
On July 21, the highly anticipated 2021 MSCI Conference—the China Pharmaceutical and Healthcare Industry Symbiosis Summit—kicked off in Kunming, drawing significant attention from the pharmaceutical industry. The highlight of the event was the grand unveiling of the 2020 China Top 100 Pharmaceutical Companies list, where Jiuzhitang Co., Ltd. made a notable appearance, ranking 28th on the "2020 China Traditional Chinese Medicine Enterprises TOP100 Ranking."
Looking back at 2020, the sudden COVID-19 pandemic profoundly impacted people's lives while also placing new demands on pharmaceutical companies. The internet-based healthcare sector seized unprecedented growth opportunities, while traditional sales channels came under significant pressure. Meanwhile, national centralized procurement continued its rapid expansion, and local initiatives in this area were gaining momentum. Additionally, the national health insurance catalog was revised annually, while provinces accelerated efforts to phase out outdated coverage options. As these multifaceted pharmaceutical policies become increasingly institutionalized, pharmaceutical companies now face a host of complex challenges and obstacles.
The 2020 China Top 100 Pharmaceutical Industry Rankings focused on the innovation drivers and professional marketing capabilities of pharmaceutical companies, evaluating them based on comprehensive R&D investment metrics. The selection was rigorously defined by analyzing quantitative data from end-user perspectives—specifically, the final choices made by clinicians and patients. Ultimately, the rankings were finalized through a rigorous quantitative analysis that integrated exclusive terminal-level data from Minenet across its three major terminals and six key market segments. This process ensured a meticulous evaluation, leveraging a scientifically sound assessment system and an objective evaluation model to comprehensively assess pharmaceutical enterprises.
Founded in 1650, Jiuzhitang has now traversed a remarkable 371-year journey. Adhering to the development philosophy of "innovating through inheritance and growing through innovation," Jiuzhitang has evolved into a leading modern, large-scale pharmaceutical enterprise listed on the stock market. It currently oversees more than 30 subsidiary companies, operates over 400 chain stores, and boasts an extensive product portfolio of more than 380 distinct formulations. The company seamlessly integrates research, production, sales, and health management, earning prestigious accolades such as "Time-Honored Brand of China" and "National-Level Intangible Cultural Heritage."
In an era of rapid and profound transformation across numerous industries, the pharmaceutical sector is facing an unprecedented upheaval. Amidst the frequent implementation of new policies, the industry’s growing trend toward consolidation, and the explosive growth of online pharmaceutical e-commerce, the healthcare industry urgently needs to identify clear pathways for sustained growth.
Jiuzhitang is attuned to the pulse of the times, staying committed to the traditional Chinese medicine field while preserving and promoting the time-honored cultural heritage of "China's Time-Honored Brands." At the same time, the company consistently invests in scientific and evidence-based research on the intrinsic value of its classic herbal products. Beyond its deep-rooted expertise in traditional Chinese medicine, Jiuzhitang has expanded its business portfolio into cutting-edge areas such as biopharmaceuticals, health products derived from the concept of "medicine and food sharing the same origin," medical healthcare services, and innovative internet marketing strategies. In terms of innovation, Jiuzhitang has proactively positioned itself in emerging therapeutic areas, including stem-cell therapies and groundbreaking drugs like YB209, YB211, and REMD477, all of which have already achieved significant milestone advancements. Notably, in July 2021, the innovative drug YB209 (also known as the LFG project) received written approval from the U.S. Food and Drug Administration (FDA), clearing the way for clinical trials in the United States. Meanwhile, in the realm of digital marketing and online healthcare, Jiuzhitang is steadily building two key platforms—centered around e-commerce and an internet hospital infrastructure—aiming to establish a robust, eco-friendly business ecosystem. The company is actively exploring broader opportunities for growth and collaboration, paving the way for sustainable expansion in the digital age.
Embracing a new ecosystem, integrating into a fresh order, and striving for a brighter future. Jiuzhitang will continue to uphold its core value of "Jiuzhitang: A Century of Commitment to Greater Health," keeping pace with the times while relentlessly pursuing a development model centered on "driving innovation and delivering high-quality offerings—leading and shaping new consumer demands." This approach will ensure that the iconic Jiuzhitang brand shines once again, positioning the company as a global leader in the health industry.
Related News
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy